摘要
目的:评价复方苦参注射液联合肝动脉灌注化疗栓塞术(TACE)治疗原发性肝癌(PLC)的疗效与安全性。方法:检索1994-2011年10月的CNKI、VIP、PubMed数据库及Cochrane图书馆中有关复方苦参注射液联合TACE治疗PLC的随机临床试验文献,将符合纳入标准的文献进行质量评估及Meta分析。结果:纳入的14篇文献均为低质量文献,Jadad评分均为1分。试验组与对照组相比,有效率RR为1.88,95%CI[1.38,2.25],(P<0.0001);Karnofsky评分(KPS)RR为3.66,95%CI[2.31,5.80],(P<0.00001);1年生存率RR为1.42,95%CI[1.14,1.77],(P=0.002);2年生存率RR为1.62,95%CI[1.04,2.53],(P=0.03);试验组均显著优于对照组。恶心呕吐发生率RR为0.57,95%CI[0.43,0.75],(P<0.0001);发热发生率RR为0.66,95%CI[0.56,0.78],(P<0.00001);腹痛发生率RR为0.60,95%CI[0.48,0.74],(P<0.00001);肝功损伤发生率RR为0.70,95%CI[0.60,0.81],(P<0.00001);试验组均显著低于对照组。结论:虽然现有证据表明PLC患者在行TACE治疗时联合应用复方苦参注射液,不仅可提高患者的有效率、KPS评分、1、2年生存率,而且可减轻TACE术后的呕吐、腹痛、发热、肝功能损伤等不良反应,但由于缺乏高质量的文献,上述结论仍有待进一步证实。
Objective：To evaluate effectiveness and safety of compound Kushen Injection combined with transcatheter arterial chemoembolization（TACE）for primary carcinoma of liver（PLC）.Methods：We selected the articles about the randomized clinical trials in the therapy that compound Kushen Injection combined with TACE for PLC（the trial group）compared with TACE alone（the control group）by searching MEDLINE,CNKI,VIP and PUBMED database and the Cochrane Library.The quality of included studies was assessed and meta analysis was performed by Revmman5.0 software.Results：Compared with the control group,the risk ratio（RR）of the effective rate of the trial group was 1.88,95%CI（confidence interval）[1.38,2.25]（P0.0001）;RR of the Karnofsky performance score（KPS）was 3.66,95%CI [2.31,5.80]（P0.00001）;RR of the 1 year survival rate was 1.42,95% CI [1.14,1.77]（P=0.002）;RR of the 2 year survival rate was 1.62,95%CI [1.04,2.53]（P=0.03）.All diffrences were statistically significant.RR of the incidence of nausea and vomiting was 0.57,95%CI [0.43,0.75]（P0.0001）;RR of the incidence of fever was 0.66,95%CI [0.56,0.78]（P0.00001）;RR of the incidence of abdominal pain was 0.60,95%CI [0.48,0.74]（P0.00001）;RR of the incidence of hepatic injury was 0.70,95%CI [0.60,0.81]（P0.00001）.All diffrences were statistically significant too.The result of the funnel plot analysis implied that there was a publication bias.Conclusion：Compound Kushen Injection combined with TACE for PLC can not only improve the effectiveness rate,KPS and 1or 2 year survival rate,but also reduce the incidence rate of the clinical adverse effects such as nausea and vomiting,fever,abdominal pain and hepatic injury.However,the conclusion needs to be proved by further experiments on account of the absence of high quality articles.
出处
《中华中医药学刊》
CAS
2013年第5期1193-1195,共3页
Chinese Archives of Traditional Chinese Medicine
关键词
复方苦参注射液
肝动脉灌注化疗栓塞术
原发性肝癌
META分析
compound Kushen Injection
transcatheter arterial chemoembolization
primary carcinoma of liver
meta-analysis
